MR. BUCKET (The Hidden)
#9658; #9658; #9658; Enjoy the video? Subscribe! bit.ly #9668; #9668; #9668; Download Here: http://www.hidden-source.com What is The Hidden? "In the early 1950s human genetics experimentation was taking its first, tentative steps. Amongst many other black projects, a team of British scientists working at an Infinitum Research experimental station stumbled across some remarkable phenomena involving DNA manipulation. This led to deeper research with dangerously unpredictable results, often leading to human patients losing their lives in irresponsible and immoral experiments. Time passed on, and by the mid 1990s the failure rate of the experiments had been reduced from 75% to a mere 15%, enough for Infinitum to move onto the next stage Biological Light Refraction. The British team were hoping to unravel the possibilities of light manipulation to create the perfect covert military agent. Early into the new millennium, due to a gross miscalculation, a series of tests on Subject 617 led to a massive synaptic trauma leaving the patient with multiple genetic anomalies. The subject was left in constant pain and with unstable DNA. The subject escaped captivity, killing anyone that got in its way. The IRIS (Infinitum Research Interception Squad) team have been deployed to return the subject to a maximum security Infinitum Research facility for further study and dissection. The entire project was considered a failure: all funding ceased and development was discontinued while all records and traces of the experiments ...

By: SeaNanners

Continued here:
MR. BUCKET (The Hidden) - Video

Recommendation and review posted by Bethany Smith

The Banana Hotline
The Banana Hotline by Fallen Fruit RING RING!! The Banana Hotline is a 24 hour a day open platform for sharing your dreams and wishes. All the bananas in the world are the same genetics and are connected in the most basic way. They are distrubuted all over the world everyday for our entire lives. Bananas are like telephones, pick one up, hit record and send us your message! Fallen Fruit is a long-term art collaboration that began by mapping fruit trees growing on or over public property in Los Angeles. The collaboration has expanded to include serialized public projects and site-specific installations and happenings in various cities around the world. By always working with fruit as a material or media, the catalogue of projects and works reimagine public interactions with the margins of urban space, systems of community and narrative real-time experience.

By: DavidBurnsProjects

Continued here:
The Banana Hotline - Video

Recommendation and review posted by Bethany Smith

IOWA CITY, Iowa (AP) A growing number of universities are offering classes on personal genetics to educate students about a medical field that is becoming increasingly important as the price of genetic testing drops. Here's a look at the basics:

Q: What is genetic testing and genotyping?

A: A genetic test analyzes DNA to look for a specific gene to test for the presence of a condition, such as Huntington's disease. Genotyping goes far beyond that, analyzing several or even thousands of variants across an individual's full set of genes, known as the genome.

Q: How can you get such testing done?

A: Medical providers use the testing routinely. It helps them diagnose patients who have symptoms of a disease, screen newborn infants for disease risks, tell parents whether their unborn child will have a genetic condition, and determine the amount and type of medicine best suited for a patient.

But what is becoming more available and common is testing done by private companies marketing services directly to consumers, such as 23AndMe and AncestryDNA. These tests typically analyze thousands of different variants but do not look at the entire genome. The tests can cost $99 to more than $1,000, depending on the extent of testing done. 23AndMe and AncestryDNA require individuals to submit saliva samples, and initial results can be available within six weeks.

Q: What can the results show?

A: The results can show whether individuals are at increased risk for a range of diseases; whether they are a carrier for hundreds of genetic conditions; whether they are predisposed to have certain physical traits; where one's ancestors come from; how they may respond to certain drugs.

Q: What are some practical ways this can help?

A: The information can help diagnose potential health problems sooner. Individuals may be able to take steps to avoid behavior that may trigger health problems for which they know they're at risk. Couples who learn they are carriers for the same disease may conceive with egg or sperm donors to avoid passing it to children. Individuals may be able to identify and meet relatives they did not know.

Read the original post:
Q&A: The science behind personal genetics testing

Recommendation and review posted by Bethany Smith

RUTHERFORD, N.J.--(BUSINESS WIRE)--

Cancer Genetics, Inc. (CGI), a leader in oncology-focused personalized medicine, today announced it has received CLIA and New York State approvals for clinical use of its proprietary mature B-cell neoplasm array or MatBA (patent 13/475,034) for diffuse large B-cell lymphoma. MatBA-DLBCL will assist clinicians in the diagnosis and prognosis of DLBCL.

DLBCL is the most common form of non-Hodgkin lymphoma (NHL), a diverse group of hematological malignancies. An estimated 190,000 people in the United State suffer from DLBCL, and up to 24,500 new U.S. cases diagnosed each year, which accounts for up to 40% of all NHL cases. Newly-diagnosed patients have a median age of 64 years, and disease progression and outcomes vary widely, due in part to the genomic characteristics of each individual patients cancer. This creates a strong clinical need for accurate and molecularly-informed prognostic testing both at the time of initial diagnosis and throughout ongoing disease monitoring efforts to ensure selection of the best treatment plan for an individual patient. However, current prognostic modalities rely primarily on clinical features.

CGIs MatBA-DLBCL microarray provides clinicians with information on genomic alterations in DLBCL, including regions of gain and loss that are associated with disease outcome.

A research collaboration between the Memorial Sloan-Kettering Cancer Center and CGI using 87 patient samples, as well as the analysis of two open datasets including 171 samples (GSE11318, Lenz et al.) and 51 high risk samples (E-MEXP-3463, Taskinen) and other published datasets showed that:

CGI believes that it is the only laboratory to have a CLIA and New York State approved microarray for the genomic assessment of DLBCL. The MatBA-DLBCL Array CGH assay joins the DLBCL CompleteSM program offered by CGI, which includes a suite of esoteric tests used in the diagnosis, prognosis and clinical management of DLBCL patients. This newly-approved DLBCL test extends CGIs ongoing commitment to developing new diagnostic and disease management tools for some of the most costly and critical unmet needs in oncology today. MatBA-DLBCL joins MatBA-CLL (chronic lymphocytic leukemia) and MatBA-SLL (small lymphocytic leukemia) in CGIs suite of CLIA- and New York State-approved proprietary microarrays for the clinical management of underserved hematological malignancies.

About Cancer Genetics, Inc.

Cancer Genetics, Inc. (CGI) is an emerging leader in the field of personalized medicine, offering products and services that enable cancer diagnostics as well as treatments that are tailored to the specific genetic profile of the individual. CGI is committed to maintaining the standard of clinical excellence through its investment in outstanding facilities and equipment. Our reference laboratory is both CLIA certified and CAP accredited. In addition, we have approvals and accreditations from the states of Florida, Maryland, New York, and New Jersey. The company has been built on a foundation of world-class scientific knowledge and IP in solid and hematologic cancers, as well as strong research collaborations with major cancer centers such as Memorial Sloan-Kettering and the National Cancer Institute.

CGIs dedicated staff takes pride in our specialized laboratory services, superior turnaround time (TAT), enhanced reporting, EMR integration, and ongoing research and development for new oncology tests. CGIs full-service cancer genetic practice and path to innovation with research makes for optimal patient care management. For further information, please see http://www.cancergenetics.com.

Here is the original post:
Cancer Genetics, Inc. Receives Regulatory Approvals for MatBA®-DLBCL, A Proprietary Microarray Test for the Diagnosis ...

Recommendation and review posted by Bethany Smith

AMES, IA--(Marketwire - Feb 28, 2013) - NewLink Genetics Corporation ( NASDAQ : NLNK ), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today reported consolidated 2012 financial results and reviewed key 2012 accomplishments.

"We have made significant progress during this past year.The enrollment rate in our pivotal phase 3 IMPRESS trial with our active cellular immunotherapy product candidate for resected pancreatic cancer, algenpantucel-L,has exceeded our original expectations.We initiated both a Phase 3 study in patients with locally advanced pancreatic cancer using algenpantucel-L, and a Phase 2B/3 adaptive design study to evaluate our active cellular immunotherapy using tergenpumatucel-L in patients with progressive or relapsed Stage IIIB/IV non-small cell lung cancer (NSCLC).In addition, weexpect to move our HyperAcute melanoma immunotherapy into controlled phase 2 studies in 2013.We are also expanding our HyperAcute immunotherapy platform to include different tumor types.Furthermore, weexpect to move the first of these into Phase 1 human studies in the second half of 2013," commented Dr. Charles Link, Chairman and Chief Executive Officer of NewLink."Rapid enrollment rate in our pivotal phase 3 IMPRESS pancreatic cancer study should enable us to complete enrollment of this trial in the summer of 2013, ahead of our original schedule."

Full Year 2012 Financial Results

Financial GuidanceNewLink expects to end 2013 with about $40 million in cash, cash equivalents and marketable securities.

Recent Accomplishments

Upcoming ActivitiesNewLink expects to present at the following conferences:

Today's Conference Call and Webcast ReminderThe NewLink management team will host a conference call discussing the company's financial results and recent corporate developments on Thursday, February 28, 2013, at 10:00am EST.The call can be accessed by dialing 1-(877) 363-5052 (domestic) or 1-(914) 495-8600 (international) five minutes prior to the start of the call and providing the passcode 16064630.A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-(855) 859-2056 (domestic) or 1-(404) 537-3406 (international), providing the passcode 16064630.The replay will be available for two weeks from the date of the live call.

About HyperAcute Immunotherapy

NewLink's HyperAcute immunotherapy technology is designed to stimulate the human immune system by exploiting a natural barrier present in humans that protects against infection being transmitted from other mammals.This barrier is related to the enzyme, alpha (1,3) galactosyl transferase, or Alpha-GT, which is expressed in the cells of lower mammals but not present in human cells.The presence of this enzyme results in the incorporation of a non-human form of carbohydrate called alpha (1,3) galactosyl carbohydrates, or Alpha-Gal, on the surface of expressing cells.Introducing Alpha-Gal expressing cells to the human immune system activates an immune response resulting from pre-existing antibodies against Alpha-Gal.Antibodies directed against the Alpha-Gal epitope are potentially the most abundant natural antibody in humans and represent approximately 1% of circulating human antibodies.

NewLink's HyperAcute cancer immunotherapy product candidates are composed of irradiated, live, allogeneic human cancer cells modified to express the gene that makes Alpha-Gal epitopes.This exposure to Alpha-Gal stimulates the human immune system to attack and destroy the immunotherapy cells on which Alpha-Gal is present by activating complement, an important component of the immune system capable of cell destruction.After destruction, NewLink believes the resulting cellular fragments bound by anti-Alpha-Gal antibodies are processed by the immune system to elicit an enhanced multi-faceted immune response to tumor-associated antigens common to both the immunotherapy and the patient's tumor cells.

Originally posted here:
NewLink Genetics Reports Fourth Quarter and Full-Year 2012 Financial Results

Recommendation and review posted by Bethany Smith

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Good Start Genetics, Inc.,an innovative molecular diagnostics company developing the new gold standard in carrier screening, announced today that it will present a company overview at the Cowen and Company 33rd Annual Health Care Conference at the Boston Marriott Copley Place. Don Hardison, president and CEO of Good Start Genetics, is scheduled to present at 9 a.m. on Tuesday, March 5.

Mr. Hardison will provide an overview of Good Start Genetics and its groundbreaking next-generation DNA sequencing based carrier screening service, as well as highlights from its first year on the market. Mr. Hardison will be available to meet with investors and media attending the conference.

Good Start Genetics recently announced that four separate abstracts related to its technology have been accepted for presentation at the upcoming annual meetings of the Pacific Coast Reproductive Society (PCRS) and the American Congress of Medical Genetics and Genomics (ACMG).

Since its national launch in April 2012, Good Start Genetics high-complexity, CLIA- and CAP-accredited laboratory has processed tens of thousands of test orders. The GoodStart Select next-generation gene sequencing technology detects common mutations in carriers across all 23 diseases recommended for testing by major medical societies as well as rare mutations that would go undetected by laboratories using older, traditional genotyping-based technologies. For example, most genotyping technologies detect about 100 mutations for cystic fibrosis (CF), while GoodStart Select detects 550 mutations.

Event

Date

Time

Place

About Good Start Genetics, Inc.

Continued here:
Good Start Genetics to Present at Cowen and Company 33rd Annual Health Care Conference

Recommendation and review posted by Bethany Smith

OMICS Group-Genetic Syndromes amp; Gene Therapy-7412-3-118
OMICS Group is an Open Access publication model that enables the dissemination of research articles to the global community. Thus, all articles published under Open Access can be accessed by anyone.

By: OMICSGroup I Articles

Continue reading here:
OMICS Group-Genetic Syndromes & Gene Therapy-7412-3-118 - Video

Recommendation and review posted by Bethany Smith

OMICS Group - Genetic Syndromes amp; Gene Therapy-7412-3-119
OMICS Group is an Open Access publication model that enables the dissemination of research articles to the global community. Thus, all articles published under Open Access can be accessed by anyone.

By: OMICSGroup I Articles

View original post here:
OMICS Group - Genetic Syndromes & Gene Therapy-7412-3-119 - Video

Recommendation and review posted by Bethany Smith

19 - Direction of Current Research - Interview with Dr. Veena Rao
For additional information visit http://www.cancerquest.org In this video, Dr. Veena Rao talks about the ultimate goal and direction of her research with gene therapy and BRACO1. To learn more about cancer and watch additional interviews, please visit the CancerQuest website at http://www.cancerquest.org

By: CancerQuest

See the original post here:
19 - Direction of Current Research - Interview with Dr. Veena Rao - Video

Recommendation and review posted by Bethany Smith

18 - Gene Therapy and Cancer Prevention - Interview with Dr. Veena Rao
For additional information visit http://www.cancerquest.org In this video, Dr. Veena Rao discusses how gene therapy can lead to better cancer prevention. To learn more about cancer and watch additional interviews, please visit the CancerQuest website at http://www.cancerquest.org

By: CancerQuest

Continue reading here:
18 - Gene Therapy and Cancer Prevention - Interview with Dr. Veena Rao - Video

Recommendation and review posted by Bethany Smith

17 - Gene Therapy - Interview with Dr. Veena Rao
For additional information visit http://www.cancerquest.org In this video, Dr. Veena Rao explains what gene therapy is, the different types of gene therapy, and how it is relevant with her research with the BRACO1 gene. To learn more about cancer and watch additional interviews, please visit the CancerQuest website at http://www.cancerquest.org

By: CancerQuest

Here is the original post:
17 - Gene Therapy - Interview with Dr. Veena Rao - Video

Recommendation and review posted by Bethany Smith

Personalized Medicine: Are We There Yet? by Marylyn Ritchie
A central goal of identifying genetic variation for complex human traits is using that data for treatment and prevention of common diseases. Learn where the state of the art is in using genetic information for personalizing our health care. Presented by Penn State #39;s Marylyn Ritchie on 2/9/2013.

By: PennStateScience

Read the original here:
Personalized Medicine: Are We There Yet? by Marylyn Ritchie - Video

Recommendation and review posted by sam

CMC Spinal Cord Injury Mela 2013 - Female staff
Part of the staff skit for the 2013 Spinal Cord Injury Mela - female staff dance I dont think i will win an Oscar for my performance

By: Charlie Hogg

More:
CMC Spinal Cord Injury Mela 2013 - Female staff - Video

Recommendation and review posted by sam

Aubrey de Grey - SENS Research Foundation - Regenerative Medicine - XFF 2012

By: Adam Ford

Read the rest here:
Aubrey de Grey - SENS Research Foundation - Regenerative Medicine - XFF 2012 - Video

Recommendation and review posted by sam

Cell Therapy Center Emcell
The World #39;s Largest Clinical Experience in Fetal Stem Cell Transplantation Stem Cell Treatment for Various Diseases And Conditions. Anti-Aging Treatment

By: emcellsite

Read the rest here:
Cell Therapy Center Emcell - Video

Recommendation and review posted by simmons

Public release date: 28-Feb-2013 [ | E-mail | Share ]

Contact: Karen Richardson krchrdsn@wakehealth.edu 336-716-4453 Wake Forest Baptist Medical Center

WINSTON-SALEM, N.C. Feb. 28, 2013 Researchers at Wake Forest Baptist Medical Center and colleagues have identified a special population of adult stem cells in bone marrow that have the natural ability to migrate to the intestine and produce intestinal cells, suggesting their potential to restore healthy tissue in patients with inflammatory bowel disease (IBD).

Up to 1 million Americans have IBD, which is characterized by frequent diarrhea and abdominal pain. IBD actually refers to two conditions ulcerative colitis and Crohn's disease in which the intestines become red and swollen and develop ulcers, probably as the result of the body having an immune response to its own tissue.

While there is currently no cure for IBD, there are drug therapies aimed at reducing inflammation and preventing the immune response. Because these therapies aren't always effective, scientists hope to use stem cells to develop an injectable cell therapy to treat IBD.

The research findings are reported online in the FASEB Journal (the journal of the Federation of American Societies for Experimental Biology) by senior researcher Graca Almeida-Porada, M.D., Ph.D., professor of regenerative medicine at Wake Forest Baptist's Institute for Regenerative Medicine, and colleagues.

The new research complements a 2012 report by Almeida-Porada's team that identified stem cells in cord blood that are involved in blood vessel formation and also have the ability to migrate to the intestine.

"We've identified two populations of human cells that migrate to the intestine one involved in blood vessel formation and the other that can replenish intestinal cells and modulates inflammation," said Almeida-Porada. "Our hope is that a mixture of these cells could be used as an injectable therapy to treat IBD."

The cells would theoretically induce tissue recovery by contributing to a pool of cells within the intestine. The lining of the intestine has one of the highest cellular turnover rates in the body, with all cell types being renewed weekly from this pool of cells, located in an area of the intestine known as the crypt.

In the current study, the team used cell markers to identify a population of stem cells in human bone marrow with the highest potential to migrate to the intestine and thrive. The cells express high levels of a receptor (ephrin type B) that is involved in tissue repair and wound closure.

View post:
Research supports promise of cell therapy for bowel disease

Recommendation and review posted by Bethany Smith

Durham, N.C. People with heart disease have more treatment options than ever. However, sometimes nothing gets rid of continued chest pain known as angina. Researchers say they are looking at a special stem cell therapy to help those patients.

Danny Darden, 49, has heart disease and frequent chest pain despite two years worth of every treatment, surgery and medication available to stop it.

If I walk around the block, I give out and have chest pains, he said.

Duke cardiologist Dr. Tom Povsic included Darden in a phase 3 trial looking for benefits of a special stem cell therapy to stimulate the growth of new vessels feeding blood to the heart.

In certain patients, the arteries can no longer be fixed, or bypass surgery can't be used to fix the arteries. And in those patients, novel therapies are sorely needed, Povsic said. So, the stem cells in this particular case are obtained from the patient themselves.

The cells, originating in the bone marrow, are stimulated and released into the blood stream, extracted and then administered directly into the heart through a special catheter.

Last week, I was injected with the stem cells, Darden said. I'm excited to be in it, because I feel it's going to work, and even if it (doesnt) work for me, it's going to work for other people.

The study is blind, meaning Darden may have received a fake infusion. Participants are followed for two years. A smaller previous study showed promising results.

The benefit that was seen in the early study far exceeds what was seen with many medicines that are approved for angina relief, Povsic said.

Researchers say if the stem cell therapy benefits are confirmed in patients with angina, it could also be studied in patients dealing with stroke, heart attack or heart failure.

Follow this link:
Duke doctor: Stem cell therapy might help heart disease patients

Recommendation and review posted by Bethany Smith

Making Natural Product Research Work: Bubpha Techapattaraporn
The experience of BIOTEC in natural product research and the collaboration with Novartis Bubpha Techapattaraporn -- Head of Biotechnology Research section (BIOTEC, Thailand) Genetic Engineering and Biotechnology, Thailand

By: ifpma

More:
Making Natural Product Research Work: Bubpha Techapattaraporn - Video

Recommendation and review posted by Bethany Smith

More colleges and universities are offering courses that incorporate personal genetic testing, the Associated Press reports. Harvard Medical School and the Stanford University School of Medicine have offered such courses as electives for a few years, but the course the AP highlights is aimed at undergraduates.

The University of Iowa is offering an honors seminar on personal genomics that includes the option to be tested through 23andMe. The AP adds that Duke University, Stanford University, the University of Illinois, and the University of Texas also offer personal genomics courses that take advantage of a 23andMe testing discount.

Jeff Murray, the professor teaching the class, "talked through the pros and cons of testing with students, and spent two class periods examining 23andMe's consent form," the AP says. He also told them to discuss the test with their families. A few students decided not to be tested.

Iowa freshman Bakir Hajdarevic tells the AP that he was nervous that he might find out about something deleterious in his DNA, but that he was also curious to learn more and that his curiosity won out. Hajdarevic learned that he's at increased risk for being lactose intolerant and a carrier for Alpha 1-antitrypsin deficiency.

"I was kind of scared going in, like, 'Oh my God, I might have a high risk factor for some kind of cancer'," he tells the AP. "But knock on wood, according to the test, I don't really have much to worry about."

Follow this link:
Campus Genetics

Recommendation and review posted by Bethany Smith

Public release date: 27-Feb-2013 [ | E-mail | Share ]

Contact: George Hunka ghunka@aftau.org 212-742-9070 American Friends of Tel Aviv University

Tel Aviv For the estimated 250 million people worldwide who suffer from rare diseases, there is little hope for diagnosis or treatment. Because each individual disease impacts so few people, hardly any funding is allocated to research, leaving many without medical options. The US-based non-profit organization Rare Genomics Institute (RGI) is working to address this problem by "crowd-funding" allowing people to donate on the Internet towards genetic testing for individual children who are struggling with a rare disease.

Now, thanks to Dr. Noam Shomron of Tel Aviv University's Sackler Faculty of Medicine, RGI's vital mission has come to Israel the first international branch of the organization. Its online home is http://raregenomics.org/world_Israel.php, and it has launched its first appeal for two Israeli children at http://raregenomics.org/donors.php.

Based at the TAU-affiliated Sourasky Medical Center and Rabin Medical Center, RGI-Israel will help families with children impacted by rare genetic diseases find support and care through advanced genetic testing. The Israeli branch is run in collaboration with three of Israel's top geneticists, Drs. Lina Basel, Shay Ben-Shachar, and Hagit Baris.

The services that the organization provides are sorely needed in Israel, says Dr. Shomron, who is the director of Israel's RGI. Both Jewish and Arabic populations in Israel are plagued by a unique pool of genetic diseases. "There are decades of genetic puzzles in the Israeli population, and we are hoping to solve a few of them," he says, hoping that RGI-Israel will help provide the funding to support these families in need.

A community effort

A decade ago, the human genome was sequenced for the first time. The process cost over a billion dollars and took more than ten years to complete. But now a more advanced technology, deep sequencing, can sequence the entire human genome in a matter of days and at a less prohibitive cost. Dr. Shomron's TAU lab is a world leader in this field of research.

RGI's approach is straight-forward. It maintains online donation pages with pictures and personal stories of children in need of genetic testing for mutations as the first step toward treatment or a cure. Donors can then contribute to the cost of DNA testing for each individual child. "Deep sequencing costs around $1,500 per person now, and the fundraising goal for each child is less than $8,000, which is used for sequencing and confirmation of the genomes of the affected child and their relatives, depending on the family's genetic history and the genetics of the disease," says Dr. Shomron, who notes that Israeli families are already reaching out to RGI Israel for help. This allows families to avoid the difficult and expensive process of testing for mutations gene by gene.

One family, for example, has been plagued for generations by what appears to be mental retardation but the medical cause of this condition remains a mystery. "They have been living for many years without knowing what causes this problem in their family. They don't know whether their DNA is the cause and if it is, what mutation causes it," he says.

Read this article:
Crowd-sourced funding provides missing help for rare genetic diseases

Recommendation and review posted by Bethany Smith

Biblioteca Ambrosiana via LGPN

This codex of Homer's "Iliad" was produced in the late fifth century or early sixth century.

By Joel N. Shurkin Inside Science News Service

Scientists who decode the genetic history of humans by tracking how genes mutate have applied the same technique to one of the Western world's most ancient and celebrated texts to uncover the date it was first written.

The text is Homer's "Iliad," and Homer if there was such a person probably wrote it in 762 B.C., give or take 50 years, the researchers found. The "Iliad" tells the story of the Trojan War if there was such a war with Greeks battling Trojans.

The researchers accept the received orthodoxy that a war happened and someone named Homer wrote about it, said Mark Pagel, an evolutionary theorist at the University of Reading in England. His collaborators include Eric Altschuler, a geneticist at the University of Medicine and Dentistry of New Jersey, in Newark, and Andreea S. Calude, a linguist also at Reading and the Santa Fe Institute in New Mexico. They worked from the standard text of the epic poem.

The date they came up with fits the time most scholars think the "Iliad" was compiled, so the paper,published in the journal Bioessays,won't have classicists in a snit. The study mostly affirms what they have been saying, that it was written around the eighth century B.C.

That geneticists got into such a project should be no surprise, Pagel said.

"Languages behave just extraordinarily like genes," Pagel said. "It is directly analogous. We tried to document the regularities in linguistic evolution and study Homer's vocabulary as a way of seeing if language evolves the way we think it does. If so, then we should be able to find a date for Homer."

Who was Homer? It is unlikely there ever was one individual man named Homer who wrote the "Iliad." Brian Rose, professor of classical studies and curator of the Mediterranean section at the University of Pennsylvania Museum, said it is clear the "Iliad" is a compilation of oral tradition going back to the 13th century B.C.

View original post here:
Genetic tricks put a date on Homer's 'Iliad'

Recommendation and review posted by Bethany Smith

Biology Project- Gene Therapy

By: Jamie Lancaster

See the rest here:
Biology Project- Gene Therapy - Video

Recommendation and review posted by Bethany Smith

PORT ST. LUCIE, Fla.--(BUSINESS WIRE)--

Raymond F. Schinazi, Ph.D., DSc, a world leader in nucleoside chemistry and biology as well as the founder of five biotechnology companies, joins the Board of Directors of the Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a leading nonprofit immunological research institute. Dr. Schinazi, a Professor of Pediatrics and Director of the Laboratory of Biochemical Pharmacology and of the Scientific Working Eradication Group at Emorys Center for AIDS Research, brings a wealth of expertise to assist VGTI Florida on its mission of Translating Research into Health.

Selected as a 2012 Charter Fellow of the National Academy of Inventors, a prestigious distinction awarded to academic inventors whose discoveries have made a tangible impact on the quality of life and welfare of society, Dr. Schinazi will inspire the VGTI Florida community and serve as an example of effective translational research. His experience in running biotech companies and obtaining patents will help the research institute navigate the licensing and commercialization challenges associated with bringing novel technologies to the market place.

As an influential scientist, inventor, educator, and entrepreneur, were extremely pleased that Dr. Schinazi is bringing his impressive array of experience to VGTI Florida, said Jay Nelson, Ph.D., Founder and Executive Director of the institute. His remarkable accomplishments include commercialized inventions that have revenues of over $2 billion per year; in fact, more than 94% of HIV-infected individuals take at least one of the medicines he invented, saving millions of lives, Dr. Nelson added.

Dr. Schinazi is a Senior Research Career Scientist at the Atlanta VA and also an adjunct professor at Georgia State University and the University of Miami. He serves as an advisor for the Schiff Center for Liver Diseases at the University of Miami, and is a Governing Trustee for the Foundation for AIDS Research (amfAR). He has served on the Presidential Commission on AIDS and has won many awards including the Georgia Biomedical Industry Growth Award and the Distinguished Scientist Award from the Hepatitis B Foundation. Dr. Schinazi was inducted into the Technology Hall of Fame of Georgia in March 2012, and he received the Intellectual Property Legends Award in October 2012.

He has co-authored more than 470 peer-reviewed papers and 7 books; and has secured more than 90 U.S. patents. Dr. Schinazi has served on the editorial board of several peer-reviewed journals, including Antimicrobial Agents and Chemotherapy, Antiviral Chemistry and Chemotherapy, Antiviral Research and Antiviral Therapy. His current research focuses on HIV, HBV and HCV eradication strategies.

He holds a Bachelor of Science, a Ph.D. and Doctor of Science degree in Chemistry from the University of Bath, England. Dr. Schinazi completed postdoctoral training in Pharmacology at Yale University and in Virology/Immunology from Emory University.

VGTI Florida

VGTI Florida is a leading immunological research institute that is on an urgent mission to transform scientific discoveries into novel treatments and cures for devastating chronic illnesses such as cancer, HIV/AIDS, influenza and infectious diseases. VGTI Florida is an independent non-profit 501(c)(3) organization located in the Tradition Center for Innovation in Port St. Lucie, Florida. For more information, please visit http://www.VGTIFL.org.

See the original post here:
Raymond F. Schinazi, Ph.D., D.Sc., Joins the Vaccine & Gene Therapy Institute of Florida Board of Directors

Recommendation and review posted by Bethany Smith

PORT ST. LUCIE, Fla.--(BUSINESS WIRE)--

The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a leading nonprofit immunological research institute, is pleased to announce the appointment of Robert L. Lord, Jr., J.D., B.C.S., F.A.C.H.E., to the Board of Directors. Mr. Lord is Senior Vice President, Legal Services and Chief Legal Officer of Martin Health System, which serves the residents of Floridas Treasure Coast. He is currently overseeing the construction and development of the new Martin Health System Campus located adjacent to VGTI Florida in the Tradition Center for Innovation in Port St. Lucie, Florida.

Many opportunities exist for collaboration between the lifesaving research of VGTI Florida researchers and the clinical trials conducted by doctors at Martin Health System. Both organizations are helping to improve the lives of people locally and around the world.

A board certified health law expert and healthcare executive, Mr. Lord is an administrator in Martin Health overseeing matters ranging from operations, corporate compliance, risk management and planning to litigation and governmental relations. He has been a resident of the Treasure Coast since 1969.

We welcome Roberts wide ranging health law background and his wealth of experience to the VGTI Florida Board of Directors, said Jay Nelson, Ph.D., founder and Executive Director of the institute. He has his finger on the pulse of the local community and will contribute greatly to the progress of VGTI Floridas research translation into the clinical environments.

Prior to joining Martin Health System, Mr. Lord was Shareholder in the law firm of Crary, Buchanan, Bowdish, Bovie, Lord & Roby, Chartered. His practice focused on both health and media law. Prior to specializing in media and health law, he had many years of experience as a civil trial attorney.

Mr. Lord holds a Bachelor of Science from Florida State University and he received his Juris Doctorate degree from Stetson University College of Law. He is board certified by The Florida Bar in Health Law and is a Fellow of the American College of Healthcare Executives.

His professional affiliations include The Florida Bar, American Health Lawyers Association, American College of Healthcare Executives, the bars of the Florida Supreme Court and the United States Supreme Court.

VGTI Florida

VGTI Florida is a leading immunological research institute that is on an urgent mission to transform scientific discoveries into novel treatments and cures for devastating chronic illnesses such as cancer, HIV/AIDS, influenza and infectious diseases. VGTI Florida is an independent non-profit 501(c)(3) organization located in the Tradition Center for Innovation in Port St. Lucie, Florida. For more information, please visit: http://www.VGTIFL.org

Read more here:
Attorney Robert L. Lord, Jr. Joins the Vaccine & Gene Therapy Institute of Florida Board of Directors

Recommendation and review posted by Bethany Smith

Beth H. T-11 Incomplete Spinal Cord Injury at Pressing On
This is a quick sample of some of the things we focus on during one-on-on training at Pressing On. Client is Beth and she is a T-11 Incomplete Spinal Cord Injury and the trainer is Stanley Arinze. For more information on our non-profit gym for neurological disorders, visit http://www.pressingontx.org or facebook.com/pressingontx

By: pressingontx

Read the original post:
Beth H. T-11 Incomplete Spinal Cord Injury at Pressing On - Video

Recommendation and review posted by sam